Search Clinical Trials
Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.
Select a Condition or Specialty
- Allergy
- Alpha-1 Antitrypsin Deficiency
- Asthma
- Cardiology
- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19 (Coronavirus)
- Cystic Fibrosis
- Eczema (Atopic Dermatitis)
- Environmental & Occupational Health
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Food Allergy
- Gastroenterology
- Idiopathic Pulmonary Fibrosis (IPF)
- Interstitial Lung Disease (Pulmonary Fibrosis)
- Lung Cancer
- Oncology
- Pulmonary Hypertension (PH)
- Respiratory (Pulmonary)
- Rheumatology
- Sarcoidosis
All Clinical Trials
Possible New Inhaled Treatment Option for PH with ILD
Pulmonary hypertension (PH), or high blood pressure in the lungs, can often develop in those who have interstitial lung disease (ILD). Treatments for this combination of diseases, called PH-ILD, to try and improve quality of life for people with both conditions are currently being evaluated.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Six visits over approximately 52 weeks, with two initial visits for enrollment and then visits at weeks 8, 16, 24 and 52.
BEACON IPF: Bexotegrast as a Potential Treatment for IPF
As part of the BEACON IPF study, researchers are evaluating a new molecule called bexotegrast, which may provide another effective way to treat IPF symptoms.
- Gender
- Any
- Ages
- 40+
- Compensation
- Provided
- Time Required
- Eight clinic visits over 52 weeks.
Potential Treatment for Dry Skin in Pediatric Eczema Patients
In severe asthma, some of the exacerbations that cause difficulty breathing are the result of inflammation in the lung. Researchers are testing a class of anti-inflammatory drugs called a JAK1 inhibitor that has worked to treat other inflammatory conditions like eczema to see if it can help people with severe asthma.
- Gender
- Any
- Ages
- 6-12
- Compensation
- Provided
- Time Required
- Approximately 11 clinic visits spread into three periods (screening, intervention, and follow-up) over the course of two years.
AJAX Study: New Inhaled Medication for Uncontrolled Asthma
In severe asthma, some of the exacerbations that cause difficulty breathing are the result of inflammation in the lung. Researchers are testing a class of anti-inflammatory drugs called a JAK1 inhibitor that has worked to treat other inflammatory conditions like eczema to see if it can help people with severe asthma.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- 8 visits over 5 months. Visits will last between 1 and 5 hours.
VALIANT Study: A Potential New Treatment for Severe Asthma
Some people with asthma experience frequent exacerbations, involving swelling or narrowing of the airways, which causes shortness of breath, wheezing and cough. In the national study called VALIANT, researchers are evaluating a new investigational treatment called verekitug to see if it is safe and can effectively reduce inflammation to help asthma patients breathe easier.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- 19 visits over up to 70 weeks (1 year and 4 months). Two screening visits will last about 4 hours each, and all other visits will last between 4 and 6 hours.
Differences in the Pulmonary Artery of People with Pulmonary Hypertension
Pulmonary hypertension and pulmonary arterial hypertension are two conditions that can cause increased blood pressure within the lungs. The differences between the two conditions on a cellular level are not well understood, and researchers are evaluating cell samples from people that are undergoing a right heart catheterization to learn more about these two diseases and improve future care.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- One visit to review and sign consent before scheduled procedure and three follow-up phone calls (once a year for three years).
CMTX-101: IV Treatment of P. aeruginosa in Combination with Inhaled Antibiotics
People with cystic fibrosis (CF) are more vulnerable to a wide variety of bacterial infections in their lungs. One of these bacteria, Pseudomonas aeruginosa, can cause infections that decrease lung function over time. Researchers are evaluating a new therapy that may help people with CF more effectively clear these infections.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Seven clinic visits over approximately 35 days. Total study duration includes up to 60 days of screening.
Aerify3: A Potential New Treatment for Airway Inflammation in COPD
Treatments for chronic obstructive pulmonary disease (COPD) may still leave people experiencing wheezing, coughing, or shortness of breath. Researchers in the Aerify3 study are investigating a medication called itepekimab, which has shown some potential in earlier clinical trials to improve symptoms in those with COPD.
- Gender
- Any
- Ages
- 40-70
- Compensation
- Provided
- Time Required
- Approximately 9 clinic visits and 1 telephone visit, once every two weeks. Visits will take 1-4 hours
XTMAB-16: A New Drug to Reduce Steroid Use in Sarcoidosis
People with pulmonary sarcoidosis usually rely on corticosteroids to help manage symptoms. Researchers are investigating the safety of a new study drug called XTMAB-16 to see if it can help reduce corticosteroid use while treating the disease.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- Part A: A screening period for up to 42 days, followed by 12 weeks of treatment, including up to 13 clinic visits. Part B: A screening period for up to 42 days, followed by 24 weeks of treatment, including up to 19 clinic visits. After completing either part, participants will have the option to join an extension study. They will be monitored for 6 weeks after their last dose of the medication for safety and immunogenicity assessments.
Possible New Treatment for CF and NTM
Researchers in the ABATE Study are testing the safety of a drug called gallium nitrate for people with cystic fibrosis (CF) who also have been diagnosed with nontuberculous mycobacteria (NTM).
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 8 in-person visits, including two 5-day inpatient stays, and 4 phone calls over 28 weeks
Effects of Keto Diet in People with HFpEF
The keto diet has helped many people lose weight and improve their overall health. Researchers are investigating if it can also benefit people with a specific type of heart failure.
- Gender
- Any
- Ages
- 21-79
- Compensation
- Provided
- Time Required
- 12-week post-study testing is complete. There will be an option to enroll in a 12-week extension arm (for a total of 24 weeks). Primary study commitment will involve a total of 9 visits
Determining How Parenthood Affects Cystic Fibrosis Patients
Surveys have shown that a growing number of cystic fibrosis (CF) patients are considering parenthood, so steps should be taken to better understand the effects of parenthood on CF patients in order to more effectively support them.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- One survey, taking approximately 5 minutes
Potential New Treatment for Metastatic Lung Cancer
Researchers want to know if an investigational drug called SAR408701 is better than docetaxel, a chemotherapy drug already approved to treat non-small cell lung cancer (NSCLC) patients with CEACAM 5 positive tumors. The goal of this study is to determine if SAR408701 improves survival rate for NSCLC patients.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- 1 year
Treating Deployment-Related Asthma with Supplements
Many people returning from military deployment have developed asthma as a result of inhaling hazardous materials. Exposures to diesel, burn pits, biomass smoke and sandstorms during deployment likely play a role. Some people with deployment-related asthma do not respond well to standard asthma medications.
- Gender
- Any
- Ages
- 18-70
- Compensation
- Provided
- Time Required
- 5-6 clinic visits over 18-22 weeks
BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis
For many people living with cystic fibrosis, there are treatments available called cystic fibrosis transmembrane conductance regulator (CFTR) modulators that can help treat the underlying cause of cystic fibrosis. However, more than 5,000 people living with cystic fibrosis have a change in both of their CFTR genes that makes them not expected to benefit from CFTR modulators.
- Gender
- Any
- Ages
- 18-65
- Compensation
- Provided
- Time Required
- 28 weeks with 8 in-person visits and 4 phone calls.
SUNRISE Trial for Oral Steroid Dependent Asthma
People with severe asthma are often dependent on oral corticosteroids, such as prednisone, to treat their condition. Researchers are currently investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for these steroid medications.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- 14 visits over approximately 12 months. Most visits will last about 2 hours, but a few could take up to 4 hours.
.jpg?lang=en-US&ext=.jpg)
Extensive Stage Small Cell Lung Cancer Combination Treatment
Determine the efficacy and safety of lurbinectedin (a type of chemotherapy) when combined with atezolizumab (an immunotherapy treatment) as a maintenance treatment for those with ES-SCLC.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Two or more years
.jpg?lang=en-US&ext=.jpg)
PRA023 for Systemic Sclerosis with Interstitial Lung Disease
Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD).
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- Monthly visits over 50-week timeframe
.png?lang=en-US&ext=.png)
MyAI Registry for People with Adrenal Insufficiency
To help better understand adrenal insufficiency (AI) and its progression, researchers have developed a new registry called MyAI.
- Gender
- Any
- Ages
- All Ages
- Compensation
- Not Provided
- Time Required
- Initial online survey will take 30 minutes. Follow-up surveys every six months will take five to 10 minutes. Total time involvement is 10-20 years.
Blood Test to Help Identify Cancer
Researchers want to learn if a blood test can be used to identify cancers in adults. Current or former smokers who have been diagnosed with cancer but haven’t started treatment are needed for this trial. Participants will receive a blood draw and review of their medical history with a research coordinator.
- Gender
- Any
- Ages
- 50+
- Compensation
- Provided
- Time Required
- One in-person visit for enrollment, remote follow up visit 12 months later
OCEAN Study for EGPA
People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications: mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Once a month visits for approximately 15 months
Investigational Gene Therapy for Adults with CF
Adults with Cystic Fibrosis who are unable to take CFTR modulators are being asked to participate in a clinical trial for an investigational gene therapy drug known as 4D-710.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 24 months
Predict and Prevent Lung Disease
Researchers are asking healthy adults, 25-35 years old, to join a five-year study exploring factors that may affect lung health with the goal of understanding lung disease.
- Gender
- Any
- Ages
- 25-35
- Compensation
- Provided
- Time Required
- 1 four-hour in-clinic visit, followed by remote follow up for up to 4 ½ years
.jpg?lang=en-US&ext=.jpg)
Effects of Pregnancy for Cystic Fibrosis Patients
If you are a pregnant with cystic fibrosis, consider participating in this trial to learn how pregnancy affects your health.
- Gender
- Any
- Ages
- 16+
- Compensation
- Provided
- Time Required
- 7 to 9 clinic visits
SEAL Study: Stopping Eczema and Allergy
Can allergies be prevented in infants? Researchers want to know if keeping a baby’s skin healthy and hydrated with moisturizer will prevent the child from developing allergies such as food allergies. Learn how you and your child can help researchers.
- Gender
- Any
- Ages
- Newborn to 12-weeks-old
- Compensation
- Provided
- Time Required
- Three years, with six clinic visits and weekly or monthly phone calls with researchers
Healthy People Needed for Sarcoidosis Research
Researchers are working to understand the different ways sarcoidosis, a disease that causes scarring in the lungs, develops.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- Not Specified
Skin, Airway & Esophageal Epithelial Barriers in Youth
Researchers want to better understand if the causes of asthma, eczema, food allergies, eosinophilic esophagitis and GERD can be determined at a cellular level.
- Gender
- Any
- Ages
- 2-21
- Compensation
- Provided
- Time Required
- Not Specified
Biomarkers & Hypersensitivity Pneumonitis Progression
Are biomarkers in the blood of patients with hypersensitivity pneumonitis (HP) predictive? Researchers understand if biomarkers can help doctors understand how quickly the disease will progress
- Gender
- Any
- Ages
- 18-80
- Compensation
- Not Provided
- Time Required
- Not Specified
.jpg?lang=en-US&ext=.jpg)
SUNBEAM: Studying Allergy Development in Babies
Why do babies develop food allergies and eczema? Researchers are studying factors before birth and through age 3 that may influence the development of allergic conditions.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 3 years of participation
Skin Reactions to Cancer Immunotherapy
Adults with cancer who are receiving immunotherapy are needed for a new research study to understand how immunotherapy changes the body’s immune response leading to skin reactions.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 2 visits over 3 months, with possible phone follow-up after 12 months depending on cancer treatment response
Potential New Treatment for Alpha-1 Antitrypsin Deficiency
Researchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of AATD.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- Not Specified
Understanding Allergy Development in Infants
Researchers want to know what causes food allergies, eczema and wheezing in infants. If you’re pregnant, you may be able to help find the answer.
- Gender
- Any
- Ages
- 0-50
- Compensation
- Provided
- Time Required
- 3 in person visits and 1 telephone call, followed by 4 optional visits
Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?
Patients with medically inoperable stage I/IIA non-small cell lung cancer (NSCLC) who have not received prior anticancer therapy for lung cancer, may qualify for a clinical trial investigating if the combination of pembrolizumab (MK-3475) and Stereotactic Body Radiation Therapy (SBRT) may help stop or slow a relapse of NSCLC compared to SBRT alone.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 7 years
Silicosis Registry
If you’ve been exposed to silica dust, like stone and concrete, you may have developed a silica-related disease. National Jewish Health is creating a registry for silicosis and related diseases in order to better understand their risk factors and prevention.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 1 clinic or phone visit lasting 1 hour, as well as 15 minute follow-up phone interviews once a year after initial visit
Predicting ILD from Hypersensitivity Pneumonitis
Anyone with hypersensitivity pneumonitis may qualify for this observational study and help researchers find patterns for predicting ILD.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- Clinic visits every 6 months over approximately 2 years (4 visits total)
Atopic Dermatitis & Skin Infections
National Jewish Health researchers are trying to determine why people with atopic dermatitis or eczema are more susceptible to bacterial infections. Learn how you can participate in our research study.
- Gender
- Any
- Ages
- 18-65
- Compensation
- Provided
- Time Required
- Up to 3 visits or approximately 3 hours
Identifying Characteristics and Patterns of Asthma
Our researchers are working to identify the clinical, physiologic, genetic and molecular characteristics of asthmatics.
- Gender
- Any
- Ages
- 5+
- Compensation
- Provided
- Time Required
- 2-4 office visits and up to 3 follow up phone calls
New Trial Medication for Pulmonary Arterial Hypertension
By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Up to 42 months
Healthy Adults Needed for Beryllium Disease Study
By participating in our study, you can help forward research on lung disease. Our researchers are hoping to learn more about the blood cells involved in the development of scarring lung diseases and create new treatment therapies.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- 5 hours over 2 visits
.jpg?lang=en-US&ext=.jpg)
Lung Injury from Military Deployment
The purpose of this study is to learn more about lung disease found in contractors and U.S. military personnel serving in Iraq and Afghanistan after September 11, 2001.
- Gender
- Any
- Ages
- 18-70
- Compensation
- Not Provided
- Time Required
- 1 to 2 visits
Link Between Rheumatoid Arthritis & Lung Disease
Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- 6 in-person visits, performed every year over 4 years
ILD & Early Rheumatoid Arthritis
Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- 5 in-person visits over 18 months
Idiopathic Pulmonary Fibrosis (IPF) & GERD
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
- Gender
- Any
- Ages
- 40-95
- Compensation
- Provided
- Time Required
- 5 visits over a 6-month period, visits are every 3 months
Immune Pathways & Development of Sarcoidosis
If you are an adult with sarcoidosis who is not on immunosuppressive therapy, you may be able to help our researchers learn more about different types of sarcoidosis and how it develops.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 2 visits
Pulmonary Fibrosis & Genetic Factors
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Not Provided
- Time Required
- Not Specified
.jpg?lang=en-US&ext=.jpg)
Understanding Skin Problems from Eczema and Food Allergies
Researchers are studying the differences in the skin and immune cells of people with food allergies and eczema, and those without.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Provided
- Time Required
- Not Specified
.jpg?width=888&height=507&ext=.jpg)
ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)
Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments.
- Gender
- Any
- Ages
- 6-65
- Compensation
- Provided
- Time Required
- 7-8 clinic visits over five to six months.
Pulmonary Arterial Hypertension & increased dose of Opsumit
The UNISUS study will compare the effectiveness and safety of a higher dose of an investigational medication called Opsumit to a lower dose in people with pulmonary arterial hypertension (PAH). The results of the UNISUS Study will provide more information about the investigational medication’s effectiveness and safety when it is given as a higher dose to adults with PAH.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.
Testing Blood’s Response to Foreign Substances
Researchers are conducting a study of how human blood cells work. Their goal is to examine how these cells respond to different bacteria and other foreign substances.
- Gender
- Any
- Ages
- 21-65
- Compensation
- Provided
- Time Required
- One 30-minute enrollment visit. A one-hour blood draw visit every 8-12 weeks for as long as the participant is interested.
Adult Trials
Possible New Inhaled Treatment Option for PH with ILD
Pulmonary hypertension (PH), or high blood pressure in the lungs, can often develop in those who have interstitial lung disease (ILD). Treatments for this combination of diseases, called PH-ILD, to try and improve quality of life for people with both conditions are currently being evaluated.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Six visits over approximately 52 weeks, with two initial visits for enrollment and then visits at weeks 8, 16, 24 and 52.
XTMAB-16: A New Drug to Reduce Steroid Use in Sarcoidosis
People with pulmonary sarcoidosis usually rely on corticosteroids to help manage symptoms. Researchers are investigating the safety of a new study drug called XTMAB-16 to see if it can help reduce corticosteroid use while treating the disease.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- Part A: A screening period for up to 42 days, followed by 12 weeks of treatment, including up to 13 clinic visits. Part B: A screening period for up to 42 days, followed by 24 weeks of treatment, including up to 19 clinic visits. After completing either part, participants will have the option to join an extension study. They will be monitored for 6 weeks after their last dose of the medication for safety and immunogenicity assessments.
Potential New Treatment for Metastatic Lung Cancer
Researchers want to know if an investigational drug called SAR408701 is better than docetaxel, a chemotherapy drug already approved to treat non-small cell lung cancer (NSCLC) patients with CEACAM 5 positive tumors. The goal of this study is to determine if SAR408701 improves survival rate for NSCLC patients.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- 1 year
Treating Deployment-Related Asthma with Supplements
Many people returning from military deployment have developed asthma as a result of inhaling hazardous materials. Exposures to diesel, burn pits, biomass smoke and sandstorms during deployment likely play a role. Some people with deployment-related asthma do not respond well to standard asthma medications.
- Gender
- Any
- Ages
- 18-70
- Compensation
- Provided
- Time Required
- 5-6 clinic visits over 18-22 weeks
BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis
For many people living with cystic fibrosis, there are treatments available called cystic fibrosis transmembrane conductance regulator (CFTR) modulators that can help treat the underlying cause of cystic fibrosis. However, more than 5,000 people living with cystic fibrosis have a change in both of their CFTR genes that makes them not expected to benefit from CFTR modulators.
- Gender
- Any
- Ages
- 18-65
- Compensation
- Provided
- Time Required
- 28 weeks with 8 in-person visits and 4 phone calls.
SUNRISE Trial for Oral Steroid Dependent Asthma
People with severe asthma are often dependent on oral corticosteroids, such as prednisone, to treat their condition. Researchers are currently investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for these steroid medications.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- 14 visits over approximately 12 months. Most visits will last about 2 hours, but a few could take up to 4 hours.
Extensive Stage Small Cell Lung Cancer Combination Treatment
Determine the efficacy and safety of lurbinectedin (a type of chemotherapy) when combined with atezolizumab (an immunotherapy treatment) as a maintenance treatment for those with ES-SCLC.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Two or more years
PRA023 for Systemic Sclerosis with Interstitial Lung Disease
Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD).
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- Monthly visits over 50-week timeframe
MyAI Registry for People with Adrenal Insufficiency
To help better understand adrenal insufficiency (AI) and its progression, researchers have developed a new registry called MyAI.
- Gender
- Any
- Ages
- All Ages
- Compensation
- Not Provided
- Time Required
- Initial online survey will take 30 minutes. Follow-up surveys every six months will take five to 10 minutes. Total time involvement is 10-20 years.
Blood Test to Help Identify Cancer
Researchers want to learn if a blood test can be used to identify cancers in adults. Current or former smokers who have been diagnosed with cancer but haven’t started treatment are needed for this trial. Participants will receive a blood draw and review of their medical history with a research coordinator.
- Gender
- Any
- Ages
- 50+
- Compensation
- Provided
- Time Required
- One in-person visit for enrollment, remote follow up visit 12 months later
OCEAN Study for EGPA
People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications: mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Once a month visits for approximately 15 months
Investigational Gene Therapy for Adults with CF
Adults with Cystic Fibrosis who are unable to take CFTR modulators are being asked to participate in a clinical trial for an investigational gene therapy drug known as 4D-710.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 24 months
Predict and Prevent Lung Disease
Researchers are asking healthy adults, 25-35 years old, to join a five-year study exploring factors that may affect lung health with the goal of understanding lung disease.
- Gender
- Any
- Ages
- 25-35
- Compensation
- Provided
- Time Required
- 1 four-hour in-clinic visit, followed by remote follow up for up to 4 ½ years
Effects of Pregnancy for Cystic Fibrosis Patients
If you are a pregnant with cystic fibrosis, consider participating in this trial to learn how pregnancy affects your health.
- Gender
- Any
- Ages
- 16+
- Compensation
- Provided
- Time Required
- 7 to 9 clinic visits
Healthy People Needed for Sarcoidosis Research
Researchers are working to understand the different ways sarcoidosis, a disease that causes scarring in the lungs, develops.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- Not Specified
Skin, Airway & Esophageal Epithelial Barriers in Youth
Researchers want to better understand if the causes of asthma, eczema, food allergies, eosinophilic esophagitis and GERD can be determined at a cellular level.
- Gender
- Any
- Ages
- 2-21
- Compensation
- Provided
- Time Required
- Not Specified
Biomarkers & Hypersensitivity Pneumonitis Progression
Are biomarkers in the blood of patients with hypersensitivity pneumonitis (HP) predictive? Researchers understand if biomarkers can help doctors understand how quickly the disease will progress
- Gender
- Any
- Ages
- 18-80
- Compensation
- Not Provided
- Time Required
- Not Specified
SUNBEAM: Studying Allergy Development in Babies
Why do babies develop food allergies and eczema? Researchers are studying factors before birth and through age 3 that may influence the development of allergic conditions.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 3 years of participation
Skin Reactions to Cancer Immunotherapy
Adults with cancer who are receiving immunotherapy are needed for a new research study to understand how immunotherapy changes the body’s immune response leading to skin reactions.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 2 visits over 3 months, with possible phone follow-up after 12 months depending on cancer treatment response
Understanding Allergy Development in Infants
Researchers want to know what causes food allergies, eczema and wheezing in infants. If you’re pregnant, you may be able to help find the answer.
- Gender
- Any
- Ages
- 0-50
- Compensation
- Provided
- Time Required
- 3 in person visits and 1 telephone call, followed by 4 optional visits
Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?
Patients with medically inoperable stage I/IIA non-small cell lung cancer (NSCLC) who have not received prior anticancer therapy for lung cancer, may qualify for a clinical trial investigating if the combination of pembrolizumab (MK-3475) and Stereotactic Body Radiation Therapy (SBRT) may help stop or slow a relapse of NSCLC compared to SBRT alone.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 7 years
Silicosis Registry
If you’ve been exposed to silica dust, like stone and concrete, you may have developed a silica-related disease. National Jewish Health is creating a registry for silicosis and related diseases in order to better understand their risk factors and prevention.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- 1 clinic or phone visit lasting 1 hour, as well as 15 minute follow-up phone interviews once a year after initial visit
Predicting ILD from Hypersensitivity Pneumonitis
Anyone with hypersensitivity pneumonitis may qualify for this observational study and help researchers find patterns for predicting ILD.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- Clinic visits every 6 months over approximately 2 years (4 visits total)
Atopic Dermatitis & Skin Infections
National Jewish Health researchers are trying to determine why people with atopic dermatitis or eczema are more susceptible to bacterial infections. Learn how you can participate in our research study.
- Gender
- Any
- Ages
- 18-65
- Compensation
- Provided
- Time Required
- Up to 3 visits or approximately 3 hours
Identifying Characteristics and Patterns of Asthma
Our researchers are working to identify the clinical, physiologic, genetic and molecular characteristics of asthmatics.
- Gender
- Any
- Ages
- 5+
- Compensation
- Provided
- Time Required
- 2-4 office visits and up to 3 follow up phone calls
New Trial Medication for Pulmonary Arterial Hypertension
By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Up to 42 months
Healthy Adults Needed for Beryllium Disease Study
By participating in our study, you can help forward research on lung disease. Our researchers are hoping to learn more about the blood cells involved in the development of scarring lung diseases and create new treatment therapies.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- 5 hours over 2 visits
Lung Injury from Military Deployment
The purpose of this study is to learn more about lung disease found in contractors and U.S. military personnel serving in Iraq and Afghanistan after September 11, 2001.
- Gender
- Any
- Ages
- 18-70
- Compensation
- Not Provided
- Time Required
- 1 to 2 visits
Link Between Rheumatoid Arthritis & Lung Disease
Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- 6 in-person visits, performed every year over 4 years
ILD & Early Rheumatoid Arthritis
Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- 5 in-person visits over 18 months
Idiopathic Pulmonary Fibrosis (IPF) & GERD
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
- Gender
- Any
- Ages
- 40-95
- Compensation
- Provided
- Time Required
- 5 visits over a 6-month period, visits are every 3 months
Immune Pathways & Development of Sarcoidosis
If you are an adult with sarcoidosis who is not on immunosuppressive therapy, you may be able to help our researchers learn more about different types of sarcoidosis and how it develops.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 2 visits
Pulmonary Fibrosis & Genetic Factors
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Not Provided
- Time Required
- Not Specified
Understanding Skin Problems from Eczema and Food Allergies
Researchers are studying the differences in the skin and immune cells of people with food allergies and eczema, and those without.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Provided
- Time Required
- Not Specified
ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)
Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments.
- Gender
- Any
- Ages
- 6-65
- Compensation
- Provided
- Time Required
- 7-8 clinic visits over five to six months.
Pulmonary Arterial Hypertension & increased dose of Opsumit
The UNISUS study will compare the effectiveness and safety of a higher dose of an investigational medication called Opsumit to a lower dose in people with pulmonary arterial hypertension (PAH). The results of the UNISUS Study will provide more information about the investigational medication’s effectiveness and safety when it is given as a higher dose to adults with PAH.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.
Testing Blood’s Response to Foreign Substances
Researchers are conducting a study of how human blood cells work. Their goal is to examine how these cells respond to different bacteria and other foreign substances.
- Gender
- Any
- Ages
- 21-65
- Compensation
- Provided
- Time Required
- One 30-minute enrollment visit. A one-hour blood draw visit every 8-12 weeks for as long as the participant is interested.
Pediatric Trials
Potential Treatment for Dry Skin in Pediatric Eczema Patients
In severe asthma, some of the exacerbations that cause difficulty breathing are the result of inflammation in the lung. Researchers are testing a class of anti-inflammatory drugs called a JAK1 inhibitor that has worked to treat other inflammatory conditions like eczema to see if it can help people with severe asthma.
- Gender
- Any
- Ages
- 6-12
- Compensation
- Provided
- Time Required
- Approximately 11 clinic visits spread into three periods (screening, intervention, and follow-up) over the course of two years.
MyAI Registry for People with Adrenal Insufficiency
To help better understand adrenal insufficiency (AI) and its progression, researchers have developed a new registry called MyAI.
- Gender
- Any
- Ages
- All Ages
- Compensation
- Not Provided
- Time Required
- Initial online survey will take 30 minutes. Follow-up surveys every six months will take five to 10 minutes. Total time involvement is 10-20 years.
SEAL Study: Stopping Eczema and Allergy
Can allergies be prevented in infants? Researchers want to know if keeping a baby’s skin healthy and hydrated with moisturizer will prevent the child from developing allergies such as food allergies. Learn how you and your child can help researchers.
- Gender
- Any
- Ages
- Newborn to 12-weeks-old
- Compensation
- Provided
- Time Required
- Three years, with six clinic visits and weekly or monthly phone calls with researchers
Skin, Airway & Esophageal Epithelial Barriers in Youth
Researchers want to better understand if the causes of asthma, eczema, food allergies, eosinophilic esophagitis and GERD can be determined at a cellular level.
- Gender
- Any
- Ages
- 2-21
- Compensation
- Provided
- Time Required
- Not Specified
SUNBEAM: Studying Allergy Development in Babies
Why do babies develop food allergies and eczema? Researchers are studying factors before birth and through age 3 that may influence the development of allergic conditions.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 3 years of participation
Understanding Allergy Development in Infants
Researchers want to know what causes food allergies, eczema and wheezing in infants. If you’re pregnant, you may be able to help find the answer.
- Gender
- Any
- Ages
- 0-50
- Compensation
- Provided
- Time Required
- 3 in person visits and 1 telephone call, followed by 4 optional visits
Identifying Characteristics and Patterns of Asthma
Our researchers are working to identify the clinical, physiologic, genetic and molecular characteristics of asthmatics.
- Gender
- Any
- Ages
- 5+
- Compensation
- Provided
- Time Required
- 2-4 office visits and up to 3 follow up phone calls
Understanding Skin Problems from Eczema and Food Allergies
Researchers are studying the differences in the skin and immune cells of people with food allergies and eczema, and those without.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Provided
- Time Required
- Not Specified
ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)
Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments.
- Gender
- Any
- Ages
- 6-65
- Compensation
- Provided
- Time Required
- 7-8 clinic visits over five to six months.
Healthy Participant Trials
Possible New Inhaled Treatment Option for PH with ILD
Pulmonary hypertension (PH), or high blood pressure in the lungs, can often develop in those who have interstitial lung disease (ILD). Treatments for this combination of diseases, called PH-ILD, to try and improve quality of life for people with both conditions are currently being evaluated.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Six visits over approximately 52 weeks, with two initial visits for enrollment and then visits at weeks 8, 16, 24 and 52.
Extensive Stage Small Cell Lung Cancer Combination Treatment
Determine the efficacy and safety of lurbinectedin (a type of chemotherapy) when combined with atezolizumab (an immunotherapy treatment) as a maintenance treatment for those with ES-SCLC.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Two or more years
PRA023 for Systemic Sclerosis with Interstitial Lung Disease
Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD).
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- Monthly visits over 50-week timeframe
MyAI Registry for People with Adrenal Insufficiency
To help better understand adrenal insufficiency (AI) and its progression, researchers have developed a new registry called MyAI.
- Gender
- Any
- Ages
- All Ages
- Compensation
- Not Provided
- Time Required
- Initial online survey will take 30 minutes. Follow-up surveys every six months will take five to 10 minutes. Total time involvement is 10-20 years.
Predict and Prevent Lung Disease
Researchers are asking healthy adults, 25-35 years old, to join a five-year study exploring factors that may affect lung health with the goal of understanding lung disease.
- Gender
- Any
- Ages
- 25-35
- Compensation
- Provided
- Time Required
- 1 four-hour in-clinic visit, followed by remote follow up for up to 4 ½ years
Healthy People Needed for Sarcoidosis Research
Researchers are working to understand the different ways sarcoidosis, a disease that causes scarring in the lungs, develops.
- Gender
- Any
- Ages
- 18-80
- Compensation
- Provided
- Time Required
- Not Specified
Atopic Dermatitis & Skin Infections
National Jewish Health researchers are trying to determine why people with atopic dermatitis or eczema are more susceptible to bacterial infections. Learn how you can participate in our research study.
- Gender
- Any
- Ages
- 18-65
- Compensation
- Provided
- Time Required
- Up to 3 visits or approximately 3 hours
Understanding Skin Problems from Eczema and Food Allergies
Researchers are studying the differences in the skin and immune cells of people with food allergies and eczema, and those without.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Provided
- Time Required
- Not Specified
ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)
Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments.
- Gender
- Any
- Ages
- 6-65
- Compensation
- Provided
- Time Required
- 7-8 clinic visits over five to six months.